此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Women-Focused PrEP Intervention (Just4Us)

2020年11月12日 更新者:Anne Teitelman、University of Pennsylvania

Developing a Women-Focused PrEP Intervention for HIV Prevention

Many women at high risk for acquiring HIV infection are not aware of preexposure prophylaxis (PrEP), an efficacious, self-administered, woman-controlled, HIV prevention product. The objective of this study is to evaluate the feasibility and acceptability of a theory-based intervention to promote PrEP uptake and adherence in a pilot trial among 80 women. The study will also measure intention to use PrEP and actual initiation of PrEP use. The investigators hypothesize that the intervention will be acceptable and feasible and that the intervention group will report higher levels of PrEP uptake, intention to use and adhere to PrEP, and other variables regarding PrEP uptake, comparing baseline, post-intervention and 3 month follow-up assessments.

研究概览

详细说明

The HIV epidemic among women in the US is a major public health issue and many women at high risk for acquiring HIV infection are not aware of pre-exposure prophylaxis (PrEP), an efficacious, self-administered, woman-controlled, HIV prevention product. In 2014, the Centers for Disease Control and Prevention (CDC) and the American College of Obstetricians and Gynecologists (ACOG) issued guidelines for evaluating and prescribing PrEP for women at high risk for acquiring HIV. Yet, there are currently no interventions in the US to promote PrEP uptake among high risk women.

The objective of this study is to evaluate an intervention to promote PrEP uptake in two large metropolitan areas with local HIV rates that greatly exceed the national average but with different PrEP public policy and access landscapes. The investigators hypothesize that a theory-based, contextually relevant behavioral intervention combined with linkage to health care and social services, with text message support for adherence, would be feasible and acceptable and would improve PrEP uptake among high risk women.

Eligible women will be recruited primarily via face-to-face recruitment and respondent driven sampling. For respondent driven sampling, enrolled participants will be given three (3) coupons to be given to women in her social network who she thinks would be interested in joining the study. If the person referred attends a baseline visit, the referring participant will receive $10. Assessment of eligibility will be conducted by telephone or in-person. Participant initials and phone number will be recorded on the form. Eligible participants will be scheduled for a study visit at a day and time convenient for her. Study visits will be held at UPenn School of Nursing (Philadelphia) or the New York Blood Center Project Achieve office (NYC) or at a mutually agreeable location in the community that provides a private place for study procedures.

For the randomized trial, the investigators will conduct a study among 80 women to evaluate the feasibility and acceptability of the intervention. Each of the two study sites will enroll forty (40) women; thirty (30) participants will receive the theory-based, contextually tailored education and activities intervention and ten (10) participants will be randomized to the information only control group.

Prior to administering any study procedures women participants will participate in an informed consent process. During the informed consent process research staff will explained some participants will receive the education and activities intervention and some participants will receive information control group. After their questions are answered and participant signs the consent form, all participants will complete a computer-based baseline assessment and receive a rapid HIV test. All participants (control and intervention) will sign a release of information form authorizing the study team to contact the PrEP health care site for the minimal information needed to assess if PrEP was prescribed.

Randomization will be performed centrally by the project statistician, and implemented using opaque sealed envelopes. Envelopes will be numbered and shipped to each study site. Balance between arms will be maintained by use of randomly permutated blocks with unequal block sizes of 4 and 8 (to allow for the 3:1 randomization ratio), and with stratification by site (2 strata). At each site, a sealed envelope will be opened, in consecutive order, indicating study arm.

Upon completing the computer-based survey, participants randomized to the education and activities intervention arm will receive an individual tailored in-person session, conducted by a trained counselor/navigator (CN). Participants will also be asked to design simple personalized text messages for asking about PrEP initiation and PrEP adherence reminders once starting PrEP. Finally, the CN will also coordinate with the participant the best day and time to schedule her four (4) follow-up phone calls. During the phone calls, the CN will reinforce skills for PrEP uptake, review the action plan regarding identified vulnerability factors that could interfere with PrEP uptake and reinforce strategies to access referrals.

Participants randomized to the information only arm will meet with the counselor/navigator to review resources regarding PrEP and receive a list of providers/clinics prescribing PrEP.

After the session, participants will complete a post-session computer-bases survey to assess social-cognitive variables targeted in the intervention. Participants will also complete a Participant's Brief Satisfaction Questionnaire to provide feedback on the session.

All participants will be compensated $50.00 All participants enrolled will return to the study site for a three (3) month follow-up study visit to complete the computer-based survey and a questionnaire evaluating her experience navigating through the process to obtain provider appointment, medical assessment for PreP, prescription and taking PreP. Participants will be compensated $50.00 upon completing the three (3) month follow-up study visit.

研究类型

介入性

注册 (实际的)

83

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Pennsylvania
      • Philadelphia、Pennsylvania、美国、19104
        • Anne Teitelman

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 55年 (成人)

接受健康志愿者

是的

有资格学习的性别

女性

描述

Inclusion Criteria:

  • female at birth and identify as female
  • aged 18-55;
  • report unprotected vaginal or anal sex with a male partner OR any injection drug use in the past 6 months;
  • live or have sex in a high risk area or are recruited into the study by someone who lives or has sex in a high risk area;
  • understand and read English;
  • not known to be HIV-infected;
  • are willing to consider a daily pill with low rates of mild side effects to prevent HIV;
  • have access to a mobile phone.
  • report at least one of the following as 'yes' or 'do not know': current male partner who injects drugs or has sex with men; current male partner who is HIV infected; current male partner who was incarcerated in the last 6 months OR report at least one of the following as 'yes': shared injection equipment in last 6 months; in methadone, buprenorphine or suboxone treatment program in past 6 months; exchange sex for money, drugs, other goods in last 6 months; powder cocaine, crack use, methamphetamines, or ecstasy >1x/week in last 6 months; Chlamydia, syphilis, gonorrhea diagnosed or newly diagnosed genital herpes in last 6 months; alcohol abuse in last 6 months (defined as a score of 2 or higher on the CAGE36); has 3 or more male partners.

Exclusion Criteria:

  • currently using PrEP

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Education + Activities
12 modules which include the following topics: introduction to the CN and intervention, video about PrEP, PrEP use in combination with other HIV, STI, and pregnancy prevention, identification and strategizing about beliefs regarding PrEP initiation, addressing perceived risk, strategizing about vulnerability factors that may interfere with PrEP uptake, skills building for PrEP uptake, and enhanced referral to a PrEP provider. Up to 4 follow-up phone calls to reinforce strategies. Text messaging for support PrEP adherence.
Format:Video; discussion; information handouts; facilitated referral
有源比较器:Information
PrEP information brochures, frequently asked questions and questions to ask provider. Listing of local PrEP providers.
Format: Information handouts

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Intervention Fidelity
大体时间:baseline session
Evaluation of fidelity behavior for each module by site coordinator after listening to audio recordings of intervention sessions using a rating form with 90% evaluation items must be 4s or 5s on a 5-point Likert scale.
baseline session
Participant Acceptability of intervention
大体时间:baseline and 3 months
At least 80% of participants report moderate or higher levels of acceptability: based on participants' indicating favorable responses indicated by 4s and 5s on a 5 point Likert scale on the Brief Satisfaction Questionnaire
baseline and 3 months

次要结果测量

结果测量
措施说明
大体时间
PrEP uptake behavior
大体时间:3 months
PrEP uptake behavior (Preliminary Impact) as reported by self report at 3 months
3 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2018年11月3日

初级完成 (实际的)

2019年10月10日

研究完成 (实际的)

2019年11月10日

研究注册日期

首次提交

2018年9月29日

首先提交符合 QC 标准的

2018年10月5日

首次发布 (实际的)

2018年10月9日

研究记录更新

最后更新发布 (实际的)

2020年11月13日

上次提交的符合 QC 标准的更新

2020年11月12日

最后验证

2020年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • 1R34MH108437-01A1 (美国 NIH 拨款/合同)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

We are happy to make our research findings readily available for research purposes to qualified individuals within the scientific community through individual requests directed to the Co-Principal Investigators and to share all published findings with the NIH. To protect confidentiality, qualitative data will be release in summary form. Findings from the study will be transmitted both to the scientific community through presentations at conferences and via journal articles and to interested community members through presentations. At each presentation and on each publication, contact information for additional information will be provided.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅